XML 69 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]    
Schedule of stock option activity
   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2021                   
Granted   6,632,387    3.68           
Exercised                  
Cancelled/forfeited   (469,181)   5.32           
Outstanding as of September 30, 2022   6,163,206   $3.56    9.55   $ 

 

   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2021   31,962,921   $2.81    7.77   $86,075 
Granted                   
Exercised   (1,606,795)   2.52         3,658 
Cancelled/forfeited   (5,083,652)   2.57           
Outstanding as of September 30, 2022   25,272,474   $2.82    7.17   $74 

 

   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2021   9,526,727   $5.55    8.0   $13,905 
Granted                  
Exercised   (2,181,335)   2.5         1,678 
Cancelled/forfeited   (888,381)   8.04           
Outstanding as of September 30, 2022   6,457,011   $6.51    7.99   $ 

 

   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2020   30,402,801   $2.45   8.75   $885 
Granted   5,287,031    4.74          
Exercised   (2,757,671)   2.30        7,740 
Expired/forfeited   (969,240)   3.65          
Outstanding as of December 31, 2021   31,962,921   $2.81   7.77   $86,075 
                    
Exercisable as of December 31, 2021   14,777,334   $2.51   6.93   $41,622 
Vested and expected to vest as of December 31, 2021   26,660,149   $2.73   7.59   $72,705 

 

   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2020   6,490,208   $2.49    9.26   $1,174 
Granted   5,516,399    7.82           
Exercised   (1,630,925)   2.54         8,807 
Expired/Forfeited   (848,955)   2.68           
Outstanding as of December 31, 2021   9,526,727   $5.55    8.01   $13,905 
                     
Exercisable as of December 31, 2021   3,637,954   $2.95    6.24   $9,364 
Vested and expected to vest as of December 31, 2021   7,608,158   $4.81    7.68   $13,896 

 

Schedule of weighted-average assumptions
   September 30,
2022
   September 30,
2021
 
Risk-free interest rate:   2.46%   0.79%
Expected term (in years):   7.16    6.05 
Expected volatility:   42.17%   42.10%
Dividend yield:   0.00%   0.00%

 

   2021   2020 
Risk-free interest rate:   0.79%   0.45%
Expected term (in years):   6.05    6.13 
Expected volatility:   42.10%   37.25%
Dividend yield:   0.00%   0.00%

 

   2021   2020 
Risk-free interest rate:   1.39%   0.59%
Expected term (in years):   9.06    10 
Expected volatility:   35.86%   38.42%
Dividend yield:   0.00%   0.00%

 

Schedule of stock-based compensation expense
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2022   2021   2022   2021 
Research and development  $2,311   $1,879   $7,012   $2,873 
Sales and marketing   301    538    926    847 
General and administrative   707    2,636    1,855    4,801 
   $3,319   $5,053   $9,793   $8,521 
   2021   2020 
Research and development  $4,001   $941 
Sales and marketing   1,185    387 
General and administrative   6,159    8,177 
   $11,345   $9,505 

 

Restricted stock awards for employee bonus, net  2021   2020 
Research and development  $7,613   $ 
Sales and marketing   2,310     
General and administrative   8,694     
   $18,617   $